이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Novozymes 과거 수익 실적

과거 기준 확인 3/6

Novozymes은 연평균 1.5%의 비율로 수입이 증가해 온 반면, Chemicals 산업은 수입이 증가했으며, 연간 15.9%였습니다. 매출은 연평균 5.4%의 비율로 증가했습니다. Novozymes의 자기자본이익률은 21.2%이고 순이익률은 16.9%입니다.

주요 정보

1.5%

수익 성장률

2.5%

EPS 성장률

Chemicals 산업 성장	13.1%
매출 성장률	5.4%
자기자본 수익률	21.2%
순이익	16.9%
다음 실적 업데이트	03 May 2024

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Novozymes 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

BMV:NSIS N 수익, 비용 및 수입 (DKK Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Dec 23	17,899	3,024	3,325	2,017
30 Sep 23	17,825	3,209	3,291	2,013
30 Jun 23	17,736	3,425	3,319	2,027
31 Mar 23	17,805	3,628	3,284	2,010
31 Dec 22	17,553	3,676	3,198	1,986
30 Sep 22	16,858	3,418	3,292	1,951
30 Jun 22	16,252	3,108	3,108	1,911
31 Mar 22	15,546	3,093	2,995	1,912
31 Dec 21	14,951	3,146	2,828	1,982
30 Sep 21	14,563	3,175	2,492	1,995
30 Jun 21	14,233	3,044	2,397	2,037
31 Mar 21	14,002	2,895	2,308	2,008
31 Dec 20	14,012	2,825	2,299	1,905
30 Sep 20	14,297	3,093	2,303	1,850
30 Jun 20	14,570	3,020	2,431	1,893
31 Mar 20	14,679	3,273	2,497	1,968
31 Dec 19	14,374	3,154	2,459	1,966
30 Sep 19	14,357	3,069	2,492	1,959
30 Jun 19	14,311	3,238	2,398	1,939
31 Mar 19	14,351	3,116	2,351	1,859
31 Dec 18	14,390	3,226	2,334	1,852
30 Sep 18	14,349	3,183	2,322	1,897
30 Jun 18	14,271	3,194	2,308	1,837
31 Mar 18	14,311	3,154	2,382	1,849
31 Dec 17	14,531	3,119	2,470	1,901
30 Sep 17	14,572	3,131	2,486	1,895
30 Jun 17	14,382	3,063	2,468	1,887
31 Mar 17	14,273	3,077	2,439	1,866
31 Dec 16	14,142	3,050	2,414	1,865
30 Sep 16	13,880	2,936	2,434	1,841
30 Jun 16	14,012	2,929	2,477	1,880
31 Mar 16	14,032	2,861	2,464	1,931
31 Dec 15	14,002	2,823	2,462	1,896
30 Sep 15	13,731	2,734	2,390	1,906
30 Jun 15	13,393	2,630	2,342	1,878
31 Mar 15	13,005	2,539	2,324	1,812
31 Dec 14	12,459	2,526	2,276	1,766
30 Sep 14	12,218	2,484	2,338	1,688
30 Jun 14	11,970	2,413	2,311	1,614
31 Mar 14	11,934	2,379	2,332	1,577
31 Dec 13	11,746	2,200	2,321	1,528
30 Sep 13	11,617	2,132	2,253	1,533
30 Jun 13	11,519	2,085	2,283	1,536

양질의 수익: NSIS N 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: NSIS N 의 현재 순이익 이익률 (16.9%) 작년보다 낮습니다 (20.9%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: NSIS N 의 수입은 지난 5년 동안 매년 1.5% 씩 증가했습니다.

성장 가속화: NSIS N 은(는) 지난 1년 동안 마이너스 수익 성장을 기록했기 때문에 5년 평균과 비교할 수 없습니다.

수익 대 산업: NSIS N 은 지난 1년 동안 마이너스 수익 성장( -17.7% )을 기록하여 Chemicals 업계 평균( -19.5% ).

자기자본 수익률

높은 ROE: NSIS N 의 자본 수익률( 21.2% )은 높음으로 간주됩니다.

Novozymes 과거 수익 실적

과거 기준 확인 3/6

주요 정보

최근 과거 실적 업데이트

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Third quarter 2022 earnings released

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Recent updates

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Investor sentiment improves as stock rises 18%

Less than half of directors are independent

Novozymes Launches ProSilience™ HU58

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Less than half of directors are independent

Investor sentiment deteriorates as stock falls 17%

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Year 2023

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Less than half of directors are independent

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

Less than half of directors are independent

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Less than half of directors are independent

Upcoming dividend of kr.5.50 per share

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Provides Revenue Guidance for 2022

Less than half of directors are independent

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS kr.3.17 (vs kr.2.89 in 1Q 2020)

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률